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Purpose: Renal impairment in human immunodeficiency virus (HIV)-infected patients 
could potentially be caused by many factors. HIV-related renal impairment risks have been 
little studied in African Americans and Hispanics. We investigated the impact of HIV 
itself, highly active antiretroviral therapy (HAART), comorbidities, and non-HIV-related 
drug treatment on glomerular filtration rate in a predominantly African American/Hispanic 
HIV-infected population who had received HAART for at least one year. This study was a 
retrospective electronic medical record database evaluation of renal impairment risks in a 
largely African American/Hispanic HIV population obtaining medical care at an HIV clinic 
in Dallas, Texas.
Methods: Proportional hazards models were used to investigate an association between 
an estimated glomerular filtration rate decrease .25% from baseline (ie, renal impairment) 
and demographics, antiretroviral/nonantiretroviral medications, comorbidities (hyper-
tension, diabetes mellitus, hepatitis C virus [HCV] infection, hepatitis B virus [HBV] 
infection), CD4+ counts, viral load, and duration patients were monitored at the clinic 
(time on study).
Results: In total, 323 patients were evaluated: 82% males; 61% African American/12% 
Hispanic/19% Caucasian; mean age 37.9 years (standard deviation [SD] 8.5); 6% HBV-
positive; 34% HCV-positive; 29% hypertensive; 3% diabetic; 52% tenofovir-treated; mean 
weight 75.4 kg (SD, 15.4); mean estimated glomerular filtration 114.5 mL/min/1.73 m2 
(SD, 36.7) using the Modification of Diet in Renal Disease (MDRD) calculation method; 
mean creatinine clearance (from which estimated glomerular filtration was extrapolated) 
by the Cockcroft-Gault calculation method 120.6 mL/min/1.73 m2 (SD, 41.2); mean time 
on study 2.7 years (SD, 1.0 year). An estimated glomerular filtration rate decrease of 
.25% from baseline was significantly associated with time on study (P = 0.0017; hazards 
ratio [HR] = 0.999) and hypertension (HR = 1.706; P = 0.0158) by the MDRD method, 
and with age (HR = 1.039; P = 0.0077), weight (HR = 0.987; P = 0.0023), and time on 
study (HR = 0.999; P = 0.0043) by extrapolation of Cockcroft-Gault creatinine clearance 
  calculation. No specific HAART agent was associated with significant renal impairment 
risk by the definition used in this study.
Conclusion: This retrospective database study showed time on study, hypertension, weight, and 
age to be the only significant predictors of an estimated glomerular filtration rate decrease .25% 
from baseline.
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Introduction
Because highly active antiretroviral treatment (HAART) 
has transformed human immunodeficiency virus (HIV) 
infection from a progressively deteriorating fatal disease to 
a long-term, controllable condition, an increasing number 
of HIV-infected patients are living to an advanced age. As a 
consequence, these patients are being diagnosed with chronic 
diseases that contribute to renal impairment, including hyper-
tension, atherosclerotic cardiovascular disease, and diabetes 
mellitus.1,2 Kidney function has been reported to be abnormal 
in up to 30% of HIV-infected patients.3 African Americans 
comprise nearly one-half (48%) of all US HIV/autoimmune 
deficiency syndrome (AIDS) cases, acquire HIV infection 
at seven times the rate of Caucasians, and are nearly twice 
as likely to have diabetes mellitus.4,5 Thus, they appear more 
predisposed than Caucasians to developing HIV-associated 
nephropathy (90% of all reported cases) and cardiovascular 
disease.6–9
Hispanics account for 17% of US HIV/AIDS cases and 
have a 2.5-fold higher rate of acquiring new HIV infections 
compared with nonHispanic Caucasians.10 Because His-
panics more frequently have diabetes and experience more 
diabetes-related end-stage renal disease than non-Hispanic 
Caucasians,10–12 they would in theory be at greater risk of 
worsening renal function if given antiretroviral drugs that 
adversely affect the glomeruli or proximal tubules or which 
exacerbate diabetes by inducing insulin resistance.
Many studies have been performed to evaluate risk fac-
tors that may contribute to renal impairment or renal failure 
in HIV-infected patients.13–27 Some have linked certain 
antiretroviral drugs, especially tenofovir disoproxil fumar-
ate (TDF) and the protease inhibitors lopinavir/ritonavir, 
atazanavir/ritonavir, indinavir and saquinavir/ritonavir, with 
reduction in estimated glomerular filtration rate (eGFR) and 
renal tubular abnormalities.28,29 Few of these studies have 
examined populations in which the majority of patients are 
African American or Hispanic. Most renal risk assessments 
have used the Cockcroft-Gault (CG) method of calculating 
creatinine clearance (CrCl), from which a value for eGFR 
can be extrapolated.30 The CG-estimated eGFR incorporates 
body weight and gender. It may be less accurate than the 
Modification of Diet in Renal Disease (MDRD) method,31 
which has adjustment factors for female gender and African 
American race. The purpose of the current study was to evalu-
ate the relationship between demographics, antiretroviral/
nonantiretroviral medication, comorbidities, duration of HIV , 
duration of HAART, viral load, and CD4+ cell counts on the 
development of a .25% reduction in eGFR, as estimated 
by both the CG and MDRD equations, in a   predominantly 
African American and Hispanic outpatient HIV clinic 
population.
Methods
This retrospective, single-center, Phase IV electronic data-
base study was conducted at the AIDS Arms Peabody Health 
Center in Dallas, Texas, a large outpatient HIV clinic that ser-
vices the health care needs of a primarily African American 
and Hispanic HIV population. Medical records of 691 clinic 
patients followed for up to four years (2003–2008) were 
reviewed. Data that were collected from these records and 
tabulated included demographics, laboratory values, viral 
load, CD4+ cell count, comorbidities (hypertension, diabetes 
mellitus, anemia, hepatitis C [HCV], and HBV), history of 
antiretroviral and nonantiretroviral drugs received (with 
start, stop and change dates), and medication adherence 
history as assessed by prescription refill records.   Nucleoside 
reverse transcriptase inhibitors for which usage data 
were available included zidovudine, stavudine, didanosine, 
lamivudine, abacavir, TDF, emtricitabine, the lamivudine-
zidovudine fixed-dose combination tablet, the abacavir-
lamivudine-zidovudine fixed-dose   combination tablet, 
the TDF-emtricitabine fixed-dose combination tablet, and 
the abacavir-lamivudine fixed-dose combination   tablet. 
Usage data were also available for the non-nucleoside 
reverse transcriptase inhibitors efavirenz, nevirapine, and 
delavirdine, and for the protease inhibitors atazanavir, 
nelfinavir,   lopinavir/ritonavir, fosamprenavir, saquinavir, 
indinavir, and ritonavir. Package inserts for antiretroviral 
agents were consulted before these agents were prescribed 
to ensure appropriate dosing regimens based on baseline 
laboratory tests. No special renal function requirements 
outside of product labeling were applied for any individual 
antiretroviral, including TDF. Data were analyzed only for 
HAART-treated patients who had been monitored continu-
ously at the Peabody Health Center for at least one year, 
comparing disease treatment characteristics of patients 
whose eGFR fell by more than 25% from baseline with those 
having no eGFR change.
The eGFR was assessed two ways. First, it was estimated 
from CrCl values calculated by the CG formula:30
where CrCl is expressed in mL/min, age in years, weight in 
kilograms, and serum creatinine in mg/dL. Second, eGFR 
was calculated by the MDRD formula:31
CrCl = 
[(140 age)   body weight]
Serum creatinine
-×
× 72)
× 0.8
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1.154 0.203 ×( ×
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              × 1.212 (× 0.742  if African American)( if female)
Study endpoints included time from HAART initia-
tion to event (eGFR decreasing by .25% from baseline) 
in the entire study group and the TDF-treated versus non-
  TDF-treated subgroups, and the effect of comorbidities and 
concomitant antiretroviral and nonantiretroviral medica-
tions on time to .25% decrease in eGFR from baseline. 
Statistical analyses were primarily descriptive, although a 
proportional hazards model was used to analyze time to 
event (calculated .25% eGFR decrease from baseline), with 
subanalysis of TDF-treated versus non-TDF-treated patients. 
Variation in treatment duration and other variables that could 
possibly contribute to renal impairment were factored into the 
model building process. Statistical analysis was performed by 
MDC-Biomed Data Sciences-ID at GlaxoSmithKline.
Results
Data from a total of 323 patients who had been treated with 
HAART for at least one year were evaluated (Table 1). Most 
(82%) were males, and the racial/ethnic distribution was 
61% African American, 19% Caucasian, 12%   Hispanic, 
and 8% other. Mean age was 37.9 years, and mean weight 
was 75.4 kg. Of the comorbidities examined, about one-
third of the patients were HCV-positive (34%), 29% were 
Table 1 Baseline characteristics by tenofovir (TDF) status for antiretroviral therapy-exposed patients at least one year on study
TDF+ 
n = 167
TDF-  
n = 156
Total 
n = 323
gender, n (%)
  Female 38 (23%) 21 (13%) 59 (18%)
  Male 129 (77%) 135 (87%) 264 (82%)
Age, years 
  Mean (SD) 37.4 (8.0) 38.4 (9.0) 37.9 (8.5)
Race, n (%)b
  Black 96 (57%) 102 (65%) 198 (61%)
  White 41 (25%) 21 (13%) 62 (19%)
  Hispanic 19 (11%) 21 (13%) 40 (12%)
  Other 11 (7%) 12 (8%) 23 (7%)
HIV-1 RnA (log10 copies/mL)
  Median (range) 3.96 (1.69–5.75) 3.74 (1.69–5.87) 3.86 (1.69–5.87)
CD4 cell count (cells/mm3)
  Median (range) 298 (8–1664) 430 (4–1694) 343 (4–1694)
Weight (kg) 
  Mean (SD) 75.1 (15.3) 75.6 (15.6) 75.4 (15.4)
Hepatitis B status 
  Positive 13 (8%) 6 (4%) 19 (6%)
Hepatitis C status 
  Positive 57 (34%) 54 (35%) 111 (34%)
Hypertension 
  Yes 50 (30%) 44 (28%) 94 (29%)
Diabetes 
  Yes 1 (,1%) 10 (6%) 11 (3%)
Cockcroft-gault CrCl category (mL/min)
 , 30 0 1 (,1%) 1 (,1%)
  30–60 2 (1%) 3 (2%) 5 (2%)
 $ 60 140 (84%) 131 (84%) 271 (84%)
  Missing 25 (15%) 21 (13%) 46 (14%)
  Mean (SD) 120 (45.6)* 121.2 (36.2)‡  120.6 (41.2)|| 
MDRD gFR category (mL/min)
 , 30 0 1 (,1%) 1 (,1%)
  30–60 1 (,1%) 1 (,1%) 2 (,1%)
 $ 60 143 (86%) 134 (86%) 277 (86%)
  Missing 23 (14%) 20 (13%) 43 (13%)
  Mean (SD) 114 (44.4)† 115 (26.4)§ 114.5 (36.7)¶
Note: n values for certain parameters measured were as follows: *n = 142; †n = 144; ‡n = 135; §n = 136; ||n = 277; ¶ = 280. 
Abbreviations: CrCl, creatinine clearance; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; SD, standard deviation.HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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  hypertensive, 6% were HBV-positive, and 3% were diabetic. 
Fifty-two percent had been TDF-treated and 48% non-
TDF-treated. Mean baseline MDRD-assessed eGFR was 
114.5 mL/min/1.73 m2; and mean CG-assessed eGFR was 
120.6 mL/min/1.73 m2. The mean (± standard deviation [SD]) 
time on study for HAART-exposed patients monitored for 
at least one year was the same in the TDF-treated and non-
TDF-treated groups (2.7 years [SD, 1.0 year]). The mean time 
patients were specifically exposed to TDF-based HAART was 
1.8 years (SD, 1.3 years), and the time patients were exposed 
to non-TDF-based HAART was 1.7 years (SD, 1.3 years).
Using CG-assessed eGFR, proportional hazards analysis 
showed age, weight, and time on study significantly predicted 
a .25% decline from baseline in eGFR (Table 2). For each 
year of increase in age at baseline, the hazard of having 
a .25% decline from baseline in CG eGFR increased by 
3.9%. For each unit increase in weight, the hazard of having 
a .25% decline from baseline in CG eGFR decreased by 
1%, and for each additional day in the study, it decreased by 
0.1%. Using MDRD-calculated eGFR, proportional hazards 
analysis showed that time on study and a diagnosis of hyper-
tension at baseline significantly predicted a .25% eGFR 
decline (Table 2). For each additional day in the study, the 
hazard of having a .25% decline from baseline in MDRD-
assessed eGFR decreased by 0.1%. Patients with a diagnosis 
of hypertension at baseline were 1.7 times more likely to have 
a .25% decline from baseline in MDRD eGFR than those 
who were not hypertensive at baseline.
Factors that did not show a significant predictive value of 
a .25% decline by either method of assessing eGFR were 
type of antiretroviral/nonantiretroviral medications coadmin-
istered, certain comorbidities (HCV and HBV infection), and 
the magnitude of CD4+ counts and viral load. Because only 
3% of the patients were diabetics, too few were involved to 
allow a risk factor analysis of a diagnosis of diabetes mellitus 
on renal function.
Discussion
Studies of renal impairment risks in antiretroviral-treated 
HIV patients have reported discordant results, possibly 
due to differences between studies in the definition of renal 
impairment applied, racial proportions evaluated, laboratory 
values monitored, size of populations examined, duration 
over which patients were assessed or had received HAART, 
types of HAART agents used, and inclusion of patients with 
baseline low eGFR in some studies but not others.13–27 Renal 
risk factors in a predominantly African American/Hispanic 
HIV population have undergone limited study to date, despite 
these populations having a faster rate of acquiring HIV 
  infection relative to other racial or ethnic groups.6,10,32,33
Our retrospective database study in a primarily (73%) 
African American or Hispanic HIV cohort showed that time 
on study, hypertension, weight, and age were the only signifi-
cant predictors of an eGFR decrease .25% from baseline, 
and that TDF or any other specific antiretroviral agent or 
combination used, other comorbidities, baseline viral load, 
and baseline CD4+ count did not affect this endpoint. Our 
finding that increased time on study (and, hence, on HAART) 
was associated with a decline in renal function is at odds with 
what has been reported in several case reports and studies in 
which eGFR either improved or HIV-associated nephropathy 
progression slowed after HAART initiation.34–38 A reason for 
this discrepancy may stem from our population having had a 
higher mean baseline eGFR (120.6 mL/min/1.73 m2 by CG 
estimation and 114.5 mL/min/1.73 m2 by MDRD) compared 
with the HIV populations in whom improved renal func-
tion has been reported after HAART initiation. This reason 
is corroborated by data from the large Centers for AIDS 
Research Network of Integrated Clinical Systems (n = 4770), 
which showed that one year after HAART was started in 
previously treatment-naïve patients, MDRD-assessed eGFR 
improved in patients with chronic kidney disease at baseline 
(eGFR , 60 mL/min/1.73 m2), but decreased in patients with 
Table 2 Summary of proportional hazards model for Cockcroft-gault CrCl and MDRD-calculated gFR using stepwise selection 
method in antiretroviral therapy-exposed patients at least one year on study
Variable (n = 162) Parameter estimate (SD) P value Hazard ratio
CG method
Cg-estimated CrCl  0.0136 (0.0019) , 0.0001 1.014
Age, years  0.0381 (0.0143) 0.0077 1.039
Weight (lbs)  -0.0128 (0.0042) 0.0023 0.987
Time on study (days) -0.0013 (0.0004) 0.0043 0.999
MDRD method
MDRD-estimated gFR 0.0120 (0.0016) , 0.0001 1.012
Time on study (days) -0.0012 (0.0004) 0.0017 0.999
Hypertension  0.5342 (0.2213) 0.0158 1.706
Abbreviations: CrCl, creatinine clearance; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; SD, standard deviation; CG, Cockcroft-Gault.HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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initially normal renal function.39 Another factor that might 
explain the decrease rather than increase in renal function 
in our patient population is the fact that our study included 
a large proportion of African Americans, and the latter have 
a much faster rate of progression to end-stage renal disease 
than do Caucasian populations, thus making the decrements 
in eGFR in our African American cohort likely to outweigh 
increments in other study patients.40
In a larger study involving primarily African American 
patients from the Philadelphia area (n = 500; 67% African 
American), Short et al21 similarly found over one year that 
TDF therapy did not cause a significant change in MDRD-
estimated eGFR compared with a non-TDF-treated control 
arm, and that gender and diabetes were not risk factors 
for renal impairment. However, unlike our study, these 
investigators saw a significant increase in eGFR in patients 
receiving non-TDF-containing regimens, and found that 
hypertension, weight, or age did not confer greater renal 
impairment risk.
In one other renal risk study in a predominantly African 
American population (89% African American, 28% treatment-
naïve, mean HAART exposure 16 months),17 multivariate 
regression analysis showed diabetes, hyperlipidemia, base-
line MDRD-calculated eGFR . 90 mL/min/1.73 m2, and 
TDF use were associated with greater decreases in eGFR. 
TDF effects remained significant at six months (P , 0.05) 
and at the end of therapy (P = 0.05) after adjustment for age 
and baseline eGFR. A subgroup comparison of TDF-treated 
patients (n = 150) and abacavir-treated patients (n = 68) 
showed that 17% of the TDF group and 9% of the abacavir 
group experienced an eGFR decrease .30 mL/min/1.73 m2, 
and that change in eGFR at one year was greater with 
TDF (-11.48 versus -3.91 mL/min/1.73 m2 for abacavir). 
Our study included 110 patients who had taken abacavir 
as part of HAART regimens for at least one year, and 
baseline mean eGFR did not differ between patients on 
abacavir   (CG-estimated: 121 mL/min/1.73 m2; MDRD: 
113.7 mL/min/1.73 m2) and the 167 patients on TDF 
  (CG-estimated: 120.0 mL/min/1.73 m2; MDRD-estimated: 
114 mL/min/1.73 m2), with over 80% of patients in each group 
having a baseline eGFR $ 60 mL/min/1.73 m2 by either cal-
culation method (data not shown). As we found with TDF, use 
of abacavir was not associated with our particular endpoint, ie, 
an increased risk of .25% decrease in eGFR. However, it is of 
note that our study was not powered to compare TDF regimens 
with abacavir regimens regarding renal function change.
The renal impairment risk factors we observed in 
a predominantly African American/Hispanic cohort are 
comparable with those reported in US or European studies 
in large HIV-infected Caucasian populations and in studies 
in black patients in Africa.13–16,18–20,22–27,29,41 However, in all 
but two of these studies,24,41 TDF use was associated with 
either increased renal risk or greater reduction in eGFR 
compared with non-TDF users. It is possible that differ-
ences between our study results and those of other studies 
could have resulted from the definition of renal impairment 
we applied. The largest cohort analysis was a Center for 
Disease Control-sponsored evaluation of medical records 
of 9535 HIV-infected persons receiving HAART in 10 US 
cities during 2000–2003, from whom 34,814 six-month 
person-observations were made (3489 [10%] from TDF 
users and 31,325 [90%] from non-TDF users).15 Multivari-
ate analysis after 1.5 years (median) of follow-up showed 
that TDF use increased renal impairment risk (defined in 
the study as an eGFR decrease to ,90 mL/min) by 1.6 fold, 
as did hypertension by 1.5-fold, congestive heart failure by 
1.9-fold, hemoglobin (,8 mg/dL) by 4.7-fold, and CD4+ 
cell count (,50 cells/mm3) by 1.5-fold. Gender, viral load 
(.100,000   copies/mL), diabetes, wasting syndrome, and 
weight loss (.10 pounds or 10%) did not notably affect 
renal risk.15 In the large French ANRS CO3 Aquitaine 
Cohort in 2588 HIV-infected patients in whom the median 
baseline CG-calculated eGFR was 96 mL/min/1.73 m2, 
multivariate analysis showed that the occurrence of eGFR 
, 80 mL/min/1.73 m2 was increased significantly by age 
.50 years compared with younger age groups (odds ratio 
[OR] = 13.3, P , 0.0001), age 41–50 years compared with 
younger age groups (OR = 2.5, P , 0.0001), baseline body 
mass index ,22 (OR = 3.8, P , 0.0001), female gender 
(OR = 3.2, P , 0.0001), and TDF use for at least one year 
(OR = 1.6, P = 0.0016).16 The Swiss HIV Cohort study 
compared time to a 10-mL/min/1.73 m2 reduction in CG-
estimated eGFR over 24 months in treatment-naïve patients 
or patients with treatment interruptions $ 12 months after 
starting either a TDF-based combination antiretroviral 
therapy (n = 363) or a TDF-sparing regimen (n = 715).13 In 
the multiple Cox model, the risk of reaching the primary 
endpoint was increased most notably by concurrent diagnosis 
of diabetes mellitus (hazard ratio [HR] = 2.3, P = 0.008), TDF 
use (HR = 1.8, P = 0.0001) and boosted protease inhibitor 
use (HR = 1.7, P = 0.0001).
EuroSIDA, a large cohort study in 6843 HIV-positive 
people in Europe, determined factors that affect the onset of 
chronic kidney disease.29 Chronic kidney disease was defined 
as either confirmed (at least three months apart) eGFR of 
60 mL/min/1.73 m2 or less for patients with baseline eGFR of HIV/AIDS – Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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above 60 mL/min per 1.73 m2 or a confirmed 25% decline in 
eGFR for patients with baseline eGFR of 60 mL/min/1.73 m2 
or less. Poisson regression was used to determine factors 
associated with chronic kidney disease. Two hundred and 
twenty-five (3.3%) people progressed to chronic kidney dis-
ease during 21,482 person-years follow-up, ie, an incidence 
of 1.05 per 100 person-years follow-up (95% confidence 
interval [CI] 0.91–1.18); median follow-up was 3.7 years 
(interquartile range 2.8–5.7). Diagnosis of an AIDS-defining 
event, female gender, older age, developing diabetes, being 
hypertensive, and being HCV antibody-positive were all 
associated with an increased risk of chronic kidney disease. 
After adjustment for traditional factors associated with 
chronic kidney disease and other confounding variables, 
increasing cumulative exposure to TDF (incidence rate 
ratio [IRR] per year 1.16, 95% CI 1.06–1.25, P , 0.0001), 
indinavir (IRR 1.12, 95% CI 1.06–1.18, P , 0.0001), 
atazanavir (IRR 1.21, 95% CI 1.09–1.34, P = 0.0003) and 
lopinavir/ritonavir (IRR 1.08, 95% CI 1.01–1.16, P = 0.030) 
was associated with a significantly increased rate of chronic 
kidney disease.
Our study examined both CG- and MDRD-estimated 
eGFR changes because adjustments for body surface area 
and African American race differ respectively between the 
CG and MDRD methods. Higher average serum creatinine 
level (due to increased muscle mass) is one hypothesis for 
the racial difference.42 Our CG-based mean eGFR values 
consistently exceeded MDRD-based values by about 
5–10 mL/min/1.73 m2. This magnitude of discordance 
between the two methods of estimating eGFR has been 
reported previously,43 and occasionally when both CG- and 
MDRD-based estimations have been used to evaluate renal 
function in the same population, one method has suggested 
an increase from baseline in eGFR and the other suggested 
a decrease.39 With each method of assessing eGFR, time on 
study was observed as a significant risk for renal impairment. 
However, age and weight only were significant risks accord-
ing to the CG-estimated eGFR calculation method, as was 
hypertension only by the MDRD method. This underscores 
the fact that using different methods of calculating eGFR 
can lead to different risk assessment results. Indeed, the 
Swiss HIV Cohort Study found general consistency between 
CG- and MDRD-calculated risk factors for renal impairment 
(defined as time to a 10 mL/min/1.73 m2 reduction in eGFR), 
but, as in our study, notable discrepancies in risk factors were 
observable between the CG and MDRD calculation methods. 
The Swiss HIV Cohort found female gender and diabetes 
to be significant risk factors only by CG and presence of 
elevated systolic blood pressure and presence of AIDS only 
by MDRD.13
Because we did not assess renal tubular dysfunction or 
proteinuria in our study, this limited our ability to obtain a 
more complete picture of the renal condition of the study 
patients. Findings of other studies that did look at tubular 
status, by examining additional parameters such as spot-urine 
protein creatinine ratio and 24-hour markers of kidney tubul-
opathy (glycosuria, hyperaminoaciduria, hyperphosphaturia, 
and urinary β2-microglobulinuria), suggest that eGFR alone 
may not predict other pathology occurring in the kidney.41,44–46 
Thus, in the Swiss HIV Cohort study (n = 1202), although 
TDF use was associated with only a mild to moderate 
decrease in eGFR, logistic multivariable regression analysis 
showed that TDF treatment in the absence of a concurrent 
protease inhibitor was associated with a 3.3-fold higher risk 
of proximal renal tubulopathy (P = 0.001).47 Another limita-
tion of our study was that the sample was not large enough 
to discern statistical differences between African American, 
Hispanic, and Caucasian subpopulations.
In conclusion, our retrospective database study in a pre-
dominantly African American/Hispanic cohort showed time 
on study, hypertension, weight, and age to be the only signifi-
cant predictors of an eGFR decrease .25% from baseline.
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